📣 VC round data is live. Check it out!

ICU Medical Valuation Multiples

Discover ICU Medical's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Amplifon, Lepu Medical Technology, Integer Holdings, Minimed Group and more.

ICU Medical Overview

About ICU Medical

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.


Founded

1984

HQ

United States

Employees

13.0K

Website

icumed.com

Financials (LTM)

Revenue: $2B
EBITDA: $410M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

ICU Medical Financials

ICU Medical reported last 12-month revenue of $2B and EBITDA of $410M.

In the same LTM period, ICU Medical generated $866M in gross profit, $410M in EBITDA, and $199M in net income.

Revenue (LTM)


ICU Medical P&L

In the most recent fiscal year, ICU Medical reported revenue of $2B and EBITDA of $404M.

ICU Medical is profitable as of last fiscal year, with gross margin of 37%, EBITDA margin of 18%, and net margin of 9%.

See analyst estimates for ICU Medical
LTMLast FY202320242025202620272028
Revenue$2B$2B$2B$2B$2B
Gross Profit$866M$822M$740M$825M$822M
Gross Margin39%37%33%35%37%
EBITDA$410M$404M$253M$260M$298M
EBITDA Margin19%18%11%11%13%
EBIT Margin15%15%2%4%5%
Net Profit$199M$193M($30M)($118M)$732K
Net Margin9%9%(1%)(5%)0%
Net Debt-$977M---

Financial data powered by Morningstar, Inc.

ICU Medical Stock Performance

ICU Medical has current market cap of $3B, and enterprise value of $4B.

Market Cap Evolution


ICU Medical's stock price is $130.33.

ICU Medical share price decreased by 3.7% in the last 30 days, and by 1.4% in the last year.

ICU Medical has an EPS (earnings per share) of $7.72.

See more trading valuation data for ICU Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$3B-0.9%-3.7%0.9%-1.4%$7.72

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

ICU Medical Valuation Multiples

ICU Medical trades at 2.0x EV/Revenue multiple, and 10.5x EV/EBITDA.

See NTM and 2027E valuation multiples for ICU Medical

EV / Revenue (LTM)


ICU Medical Financial Valuation Multiples

As of June 3, 2026, ICU Medical has market cap of $3B and EV of $4B.

ICU Medical has a P/E ratio of 16.4x.

LTMLast FY202320242025202620272028
EV/Revenue2.0x1.9x1.9x1.8x1.9x
EV/EBITDA10.5x10.6x17.0x16.5x14.4x
EV/EBIT12.7x13.0x89.8x44.1x39.3x
EV/Gross Profit5.0x5.2x5.8x5.2x5.2x
P/E16.4x16.9x(109.8x)(27.7x)n/m
EV/FCF-51.9x59.2x37.7x51.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified ICU Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

ICU Medical Margins & Growth Rates

ICU Medical decreased revenue by 3% but EBITDA grew by 3% in the last fiscal year.

In the most recent fiscal year, ICU Medical reported gross margin of 37%, EBITDA margin of 18%, and net margin of 9%.

See estimated margins and future growth rates for ICU Medical

ICU Medical Margins

Last FY202420252026202720282029
Gross Margin37%35%37%41%
EBITDA Margin18%11%13%19%
EBIT Margin15%4%5%16%
Net Margin9%(5%)0%10%
FCF Margin4%5%4%9%

ICU Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(3%)5%(6%)(3%)
Gross Profit Growth7%11%(0%)7%
EBITDA Growth3%3%15%40%
EBIT Growth6%104%12%221%
Net Profit Growth8%297%(101%)28295%
FCF Growth141%57%(27%)141%

Data powered by FactSet, Inc. and Morningstar, Inc.

ICU Medical Operational KPIs

ICU Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

ICU Medical's Rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ICU Medical's Rule of X is 13% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for ICU Medical
LTMLast FY202320242025202620272028
Rule of 4019%17%---
Bessemer Rule of X21%13%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue4%4%4%4%4%
Opex to Revenue-32%31%31%32%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

ICU Medical Competitors

ICU Medical competitors include Amplifon, Lepu Medical Technology, Integer Holdings, Minimed Group, Medacta Group, iRhythm Holdings, MGI Tech, Haemonetics, Merit Medical Systems and Envista Holdings.

Most ICU Medical public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Amplifon1.8x1.8x8.2x8.0x
Lepu Medical Technology3.8x3.7x12.2x12.2x
Integer Holdings2.4x2.4x11.0x11.3x
Minimed Group1.3x1.1x32.3x10.3x
Medacta Group4.7x4.5x16.3x16.0x
iRhythm Holdings4.9x4.5x52.9x42.3x
MGI Tech6.5x6.2x111.7x79.2x
Haemonetics3.0x3.0x10.1x10.0x

This data is available for Pro users. Sign up to see all ICU Medical competitors and their valuation data.

Start Free Trial

Acquisitions by ICU Medical

ICU Medical has acquired 5 companies to date.

Last acquisition by ICU Medical was on September 8th 2021. ICU Medical acquired Smiths Medical for $3B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by ICU Medical

Smiths Medical
Pursuit Vascular
Pfizer (infusion therapy unit)
Tangent Medical Technologies
Description
Smiths Medical is a Minneapolis-headquartered medical device manufacturer specializing in infusion therapy, vascular access, and patient monitoring products including safety IV catheters, syringe pumps, and ECG electrodes. Serving hospitals and clinics globally from facilities in the U.S., UK, and Mexico, the company focuses on medication delivery systems and vital signs equipment acquired by ICU Medical in 2019.
Pursuit Vascular is a Minneapolis-headquartered developer of single-use catheter technologies reducing bloodstream infections. The PureIPC system targets CRBSI prevention in ICU settings, addressing CDC priorities with cost savings. Pursuit Vascular advances products through FDA pathways at pursuitvascular.com.
Pfizer (infusion therapy unit) is a division of the New York-headquartered pharmaceutical company that manufactures intravenous solutions for hospitals and clinics worldwide. The unit produces premixed antibiotics such as Zosyn and Unasyn, along with nutrition formulas and pain management injectables. Following the 2015 acquisition of Hospira, Pfizer integrated advanced infusion pumps and systems for chemotherapy delivery and central venous access. Manufacturing occurs at facilities in McPherson, Kansas; Rocky Mount, North Carolina; and Grange Castle, Ireland. These products support critical care units, operating rooms, and oncology departments across North America, Europe, and Asia Pacific.
Tangent Medical Technologies is an Ann Arbor, Michigan-based developer of intravenous infusion devices licensed from the University of Michigan. The company produces the NovaCath Closed IV Catheter System, featuring a proprietary valve to reduce needlestick injuries and bloodstream infections. Established in 2009, Tangent targets hospitals and clinics with products designed for improved patient safety and clinician efficiency.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Minneapolis, MN
Minneapolis, MN
New York City, NY
Ann Arbor, MI
Deal Date8 Sep 20214 Nov 20196 Oct 20164 Apr 2016
Valuation$3B$75M$1B$3M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all ICU Medical acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About ICU Medical

When was ICU Medical founded?ICU Medical was founded in 1984.
Where is ICU Medical headquartered?ICU Medical is headquartered in United States.
How many employees does ICU Medical have?As of today, ICU Medical has over 13K employees.
Who is the CEO of ICU Medical?ICU Medical's CEO is Vivek Jain.
Is ICU Medical publicly listed?Yes, ICU Medical is a public company listed on Nasdaq.
What is the stock symbol of ICU Medical?ICU Medical trades under ICUI ticker.
When did ICU Medical go public?ICU Medical went public in 1992.
Who are competitors of ICU Medical?ICU Medical main competitors include Amplifon, Lepu Medical Technology, Integer Holdings, Minimed Group, Medacta Group, iRhythm Holdings, MGI Tech, Haemonetics, Merit Medical Systems, Envista Holdings.
What is the current market cap of ICU Medical?ICU Medical's current market cap is $3B.
What is the current revenue of ICU Medical?ICU Medical's last 12 months revenue is $2B.
What is the current revenue growth of ICU Medical?ICU Medical revenue growth (NTM/LTM) is 1%.
What is the current EV/Revenue multiple of ICU Medical?Current revenue multiple of ICU Medical is 2.0x.
What is the current EBITDA of ICU Medical?ICU Medical's last 12 months EBITDA is $410M.
What is ICU Medical's EBITDA margin?ICU Medical's last 12 months EBITDA margin is 19%.
What is the current EV/EBITDA multiple of ICU Medical?Current EBITDA multiple of ICU Medical is 10.5x.
How many companies ICU Medical has acquired to date?As of June 2026, ICU Medical has acquired 5 companies.
What was the largest acquisition by ICU Medical?$3B acquisition of Smiths Medical on 8th September 2021 was the largest M&A ICU Medical has done to date.
What companies ICU Medical acquired?ICU Medical acquired Smiths Medical, Pfizer (infusion therapy unit), Pursuit Vascular, Excelsior Medical, and Tangent Medical Technologies.
In how many companies ICU Medical has invested to date?ICU Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to ICU Medical

Lists including ICU Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial